Search hospitals

>

Michigan

>

Kalamazoo

Ascension Borgess Cancer Center

Claim this profile

Kalamazoo, Michigan 49009

Global Leader in Breast Cancer

Global Leader in Cancer

Conducts research for Lung Cancer

Conducts research for Breast cancer

Conducts research for Pancreatic Cancer

81 reported clinical trials

1 medical researcher

Photo of Ascension Borgess Cancer Center in KalamazooPhoto of Ascension Borgess Cancer Center in KalamazooPhoto of Ascension Borgess Cancer Center in Kalamazoo

Summary

Ascension Borgess Cancer Center is a medical facility located in Kalamazoo, Michigan. This center is recognized for care of Breast Cancer, Cancer, Lung Cancer, Breast cancer, Pancreatic Cancer and other specialties. Ascension Borgess Cancer Center is involved with conducting 81 clinical trials across 229 conditions. There are 1 research doctors associated with this hospital, such as Kathleen J. Yost.

Area of expertise

1

Breast Cancer

Global Leader

Ascension Borgess Cancer Center has run 13 trials for Breast Cancer. Some of their research focus areas include:

HER2 positive
Stage IV
Stage II
2

Cancer

Global Leader

Ascension Borgess Cancer Center has run 13 trials for Cancer. Some of their research focus areas include:

Stage IV
Stage III
KRAS positive

Top PIs

Clinical Trials running at Ascension Borgess Cancer Center

Ovarian Cancer

Breast Cancer

Melanoma

Bladder Cancer

Lung Cancer

Multiple Myeloma

Cutaneous Melanoma

Breast cancer

Cancer

Uterine Cancer

Image of trial facility.

Olaparib +/- Bevacizumab

for Ovarian Cancer

This phase III trial compares the effect of olaparib for one year versus two years, with or without bevacizumab, for the treatment of BRCA 1/2 mutated or homologous recombination deficient stage III or IV ovarian cancer. Olaparib is a polyadenosine 5'-diphosphoribose polymerase (PARP) enzyme inhibitor and may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Bevacizumab is in a class of medications called antiangiogenic agents. It works by stopping the formation of blood vessels that bring oxygen and nutrients to tumor. This may slow the growth and spread of tumor. Giving olaparib for one year with or without bevacizumab may be effective in treating patients with BRCA 1/2 mutated or homologous recombination deficient stage III or IV ovarian cancer, when compared to two years of olaparib.

Recruiting

2 awards

Phase 3

4 criteria

Image of trial facility.

Targeted Therapy

for Solid Tumors

This ComboMATCH patient screening trial is the gateway to a coordinated set of clinical trials to study cancer treatment directed by genetic testing. Patients with solid tumors that have spread to nearby tissue or lymph nodes (locally advanced) or have spread to other places in the body (advanced) and have progressed on at least one line of standard systemic therapy or have no standard treatment that has been shown to prolong overall survival may be candidates for these trials. Genetic tests look at the unique genetic material (genes) of patients' tumor cells. Patients with some genetic changes or abnormalities (mutations) may benefit from treatment that targets that particular genetic mutation. ComboMATCH is designed to match patients to a treatment that may work to control their tumor and may help doctors plan better treatment for patients with locally advanced or advanced solid tumors.

Recruiting

1 award

Phase 2

17 criteria

Image of trial facility.

Blood Sample Collection

for Cancer Detection

This study collects blood and tissue samples from patients with cancer and without cancer to evaluate tests for early cancer detection. Collecting and storing samples of blood and tissue from patients with and without cancer to study in the laboratory may help researchers develop tests for the early detection of cancers.

Recruiting

1 award

N/A

9 criteria

Similar Hospitals nearby

Frequently asked questions

What kind of research happens at Ascension Borgess Cancer Center?